The Chinese Geriatric Medicine Society recently released the "Report on Advances in Geriatric Medicine and Anti-Aging Research in China." The report shows that domestic anti-aging research has shifted from traditional interventions to targeting aging mechanisms, with cellular reprogramming and senescent cell clearance emerging as two major hotspots. The report is based on surveys of 32 top-tier hospitals and research institutions nationwide, summarizing major scientific outputs from 2023 to 2024.
The report notes that a team from the Institute of Zoology, Chinese Academy of Sciences, has achieved a breakthrough in targeted senescent cell clearance. Their developed Senolytics drug combination improved cognitive function in aged mice by 30% in animal experiments, and related preclinical studies have entered the ethical review stage. Meanwhile, the Department of Geriatrics at Peking Union Medical College Hospital has launched a "Aging Biomarker Cohort" targeting individuals aged 65 and above, planning to enroll 5,000 participants to establish a personalized aging assessment system by analyzing epigenetic clocks and inflammatory factors.
Background and Significance
China is facing severe population aging challenges, with the population aged 60 and above expected to exceed 400 million by 2035. Traditional geriatric medicine focuses on disease treatment, while anti-aging research attempts to delay functional decline at its source. The report emphasizes that anti-aging interventions may reduce the incidence of chronic diseases in the elderly, such as Alzheimer's disease and cardiovascular diseases, thereby alleviating the burden on the healthcare system. Wang Chen, an academician of the Chinese Academy of Engineering, stated at the report release: "Anti-aging medicine is not about 'immortality,' but about extending healthy lifespan. This field has become part of the national strategic scientific and technological strength."
Significance for International Patients
For international patients seeking anti-aging treatments, China's research progress offers new options. For example, if clinical trials based on senescent cell clearance technology succeed, they may provide the first therapy directly targeting aging mechanisms for frail elderly patients. Additionally, the "aging biomarker" testing mentioned in the report can help patients predict functional decline risks 10-15 years in advance, enabling personalized intervention plans. Currently, renowned hospitals in Beijing, Shanghai, and Guangzhou have opened anti-aging consultation clinics, but most are still in the research stage, and international patients need to pay attention to clinical trial recruitment information.
How MedCare Can Help
As a cross-border medical platform, MedCare can assist international patients in connecting with leading geriatric medicine centers in China. We provide medical services including: scheduling international outpatient appointments at the Department of Geriatrics of Peking Union Medical College Hospital, obtaining health assessments based on the latest aging biomarker tests; and contacting institutions involved in Senolytics clinical trials to learn about enrollment criteria. Additionally, our cost estimator tool transparently displays costs for anti-aging testing items (e.g., epigenetic clock analysis, approximately RMB 8,000) and consultation fees, helping patients plan in advance. Through contact us, patients can access Chinese translation services, medical record pre-review, and follow-up support to ensure a smooth medical process.
Related reading: Overview of Partner Hospitals in Shanghai